HRP20130962T1 - Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva - Google Patents

Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva Download PDF

Info

Publication number
HRP20130962T1
HRP20130962T1 HRP20130962TT HRP20130962T HRP20130962T1 HR P20130962 T1 HRP20130962 T1 HR P20130962T1 HR P20130962T T HRP20130962T T HR P20130962TT HR P20130962 T HRP20130962 T HR P20130962T HR P20130962 T1 HRP20130962 T1 HR P20130962T1
Authority
HR
Croatia
Prior art keywords
virus
vaccine
culture
influenza virus
carried out
Prior art date
Application number
HRP20130962TT
Other languages
English (en)
Inventor
Jens Peter Gregersen
Original Assignee
Novartis Vaccines And Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35520177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130962(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines And Diagnostics Gmbh filed Critical Novartis Vaccines And Diagnostics Gmbh
Publication of HRP20130962T1 publication Critical patent/HRP20130962T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Claims (12)

1. Postupak priprave antigena cjepiva u kulturi Vero stanične linije, koji sadrži korak testiranja na patogen izabran iz skupine koja sadrži parvovirus, JC poliomavirus i cirkovirus.
2. Postupak prema patentnom zahtjevu 1, naznačen time da je patogen porcin cirkovirus.
3. Postupak prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time da se testira cjepivo i/ili virus sijač i/ili supstrat ćelije i/ili medij kulture.
4. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da se izvodi na materijalu korištenom za stvaranje virusne kulture; na virusnoj kulturi; ili na materijalu ekstrahiranom i deriviranom iz virusne kulture.
5. Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da sadrži korak u kojem se virus sijač i/ili antigen cjepiva i/ili kultura testira na prisutnost patogena izabranog iz skupine koja sadrži: viruse parainfluence; Herpesviridae; Adenoviridae; Mikoplazme; avijske cirkoviruse; te avijske Reoviridae.
6. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da se kultura testira imunokemijskom detekcijom i/ili detekcijom nukleinskih kiselina.
7. Postupak prema patentnom zahtjevu 6, naznačen time da se detekcija provodi pomoću ELI-SA i/ili PCR (uključujući RT-PCR).
8. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da se testiranje provodi za vrijeme jedne od idućih etapa: virusna zaraza, etapa rasta, pobiranje virusa, procesiranje virusa, razdjeljivanje, ekstrakcija površinskih bjelančevina, stvaranje cjepiva, pakiranje cjepiva.
9. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da se testiranje provodi kao dio normalne kontrole kvalitete.
10. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je antigen cjepiva iz virusa influence.
11. Postupak prema patentnom zahtjevu 10, naznačen time da je antigen cjepiva oslabljeni virus influence, virus influence osjetljiv na temperaturu ili virus influence prilagođen na hladnoću.
12. Postupak prema patentnom zahtjevu 10 ili 11, naznačen time da nadalje sadrži korak miješanja antigena iz više od jedne sorte virusa influence.
HRP20130962TT 2004-09-09 2013-10-10 Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva HRP20130962T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04255471 2004-09-09

Publications (1)

Publication Number Publication Date
HRP20130962T1 true HRP20130962T1 (hr) 2013-12-06

Family

ID=35520177

Family Applications (4)

Application Number Title Priority Date Filing Date
HR20100673T HRP20100673T1 (hr) 2004-09-09 2010-12-06 Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe
HR20110007T HRP20110007T1 (hr) 2004-09-09 2011-01-05 Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe
HRP20120640TT HRP20120640T1 (hr) 2004-09-09 2012-08-07 Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe
HRP20130962TT HRP20130962T1 (hr) 2004-09-09 2013-10-10 Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HR20100673T HRP20100673T1 (hr) 2004-09-09 2010-12-06 Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe
HR20110007T HRP20110007T1 (hr) 2004-09-09 2011-01-05 Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe
HRP20120640TT HRP20120640T1 (hr) 2004-09-09 2012-08-07 Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe

Country Status (16)

Country Link
US (6) US8119337B2 (hr)
EP (5) EP2236155B1 (hr)
JP (7) JP2008512443A (hr)
AT (2) ATE489965T1 (hr)
CA (2) CA2890962A1 (hr)
CY (3) CY1111180T1 (hr)
DE (3) DE602005025170D1 (hr)
DK (4) DK2236155T3 (hr)
ES (4) ES2357752T3 (hr)
HK (2) HK1105364A1 (hr)
HR (4) HRP20100673T1 (hr)
PL (4) PL2578229T3 (hr)
PT (4) PT2179744E (hr)
RS (3) RS51721B (hr)
SI (4) SI2179744T1 (hr)
WO (1) WO2006027698A1 (hr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51721B (en) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Reduction of potential iatrogenic risks associated with influenza vaccines
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
AU2006310171B2 (en) * 2005-11-01 2011-02-17 Seqirus UK Limited Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP1951299B1 (en) 2005-11-04 2012-01-04 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CA2628158C (en) 2005-11-04 2015-12-15 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
PL1976559T6 (pl) 2006-01-27 2020-08-10 Novartis Influenza Vaccines Marburg Gmbh Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
EP2010557B1 (en) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2663196A1 (en) * 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
WO2008059018A2 (en) * 2006-11-15 2008-05-22 Intervet International B.V. Vaccine for vaccinating felines and canines against influenza virus
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
SI2185191T1 (sl) 2007-06-27 2012-12-31 Novartis Ag Cepiva proti influenci z majhnimi dodatki
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
JP2012507272A (ja) 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CN102438651A (zh) 2009-02-10 2012-05-02 诺华有限公司 用于大流行相关毒株的流感疫苗方案
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20130039943A1 (en) * 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
BR112012030616A2 (pt) 2010-06-01 2017-03-01 Novartis Ag concentração de antígenos de vacina com liofilização.
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
GB201011502D0 (en) 2010-07-08 2010-08-25 Glaxosmithkline Biolog Sa Novel process
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
CA2812135A1 (en) * 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
JP5999817B2 (ja) 2011-02-25 2016-10-05 ノバルティス アーゲー 外因性の内部陽性対照
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
ES2564138T3 (es) * 2011-12-12 2016-03-18 Novartis Ag Ensayo para Hemaglutinina del virus de la influenza
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
WO2015118146A1 (en) 2014-02-10 2015-08-13 Univercells Nv System, apparatus and method for biomolecules production
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
HUE051783T2 (hu) 2015-07-07 2021-03-29 Seqirus Uk Ltd Eljárás immunogén hemagglutinin mennyiségi meghatározására
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
CN111511395B (zh) 2017-11-03 2024-10-15 武田疫苗股份有限公司 用于将寨卡病毒灭活和用于确定灭活完全性的方法
JP2022514112A (ja) * 2018-10-15 2022-02-09 リジェネクスバイオ インコーポレイテッド 複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2020226831A1 (en) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2021099419A1 (en) 2019-11-18 2021-05-27 Seqirus UK Limited Method for producing reassortant influenza viruses
WO2021150874A1 (en) * 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
WO2022187230A2 (en) * 2021-03-01 2022-09-09 Iowa State University Research Foundation, Inc. Methods and compositions for detecting and producing porcine morbillivirus and immunogenic compositions thereof
CN114107392A (zh) * 2021-11-22 2022-03-01 昆明理工大学 一种cvb5病毒类病毒样颗粒的制备方法
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193991A (en) * 1978-12-20 1980-03-18 Cornell Research Foundation, Inc. Canine parvovirus vaccine
EP0261955A3 (en) * 1986-09-26 1989-06-07 E.I. Du Pont De Nemours And Company Process for immobilization of dna
US6284492B1 (en) * 1988-02-26 2001-09-04 Large Scale Biology Corporation Recombinant animal viral nucleic acids
NZ240369A (en) 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
JPH0813753B2 (ja) * 1992-05-22 1996-02-14 株式会社微生物化学研究所 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン
IL103939A (en) * 1992-12-01 1996-09-12 Abic Ltd An anti-DBI vaccine in birds containing attenuated live DBI virus
CA2156525A1 (en) 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE4311580C1 (de) * 1993-04-12 1994-08-18 Werner Prof Dr Med Reutter Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
ATE542891T1 (de) 1994-11-10 2012-02-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freier kultur
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
GB9500788D0 (en) 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
JPH1175833A (ja) * 1997-06-23 1999-03-23 Chemo Sero Therapeut Res Inst トリレオウイルスの調製法
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
EP1037909B1 (en) * 1997-12-11 2007-06-13 University of Saskatchewan Postweaning multisystemic wasting syndrome virus from pigs
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
KR101229202B1 (ko) * 2002-04-26 2013-02-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
EP1520008B1 (en) * 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
JP3957188B2 (ja) * 2002-10-25 2007-08-15 ▲あき▼夫 友田 抗ウィルス剤
US20040176272A1 (en) 2003-01-30 2004-09-09 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
EP2494986A1 (en) * 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
RS51721B (en) * 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Reduction of potential iatrogenic risks associated with influenza vaccines
RU2519210C2 (ru) 2007-06-14 2014-06-10 Дзе Борд Оф Риджентс Фор Оклахома Стейт Юниверсити Вакцины, содержащие генетические варианты парвовируса собак

Also Published As

Publication number Publication date
US8119337B2 (en) 2012-02-21
CA2579859C (en) 2015-12-08
PT1789084E (pt) 2011-02-22
SI2179744T1 (sl) 2011-04-29
EP2236155B1 (en) 2012-05-16
ES2357752T3 (es) 2011-04-29
DK1789084T3 (da) 2011-01-10
HK1105364A1 (en) 2008-02-15
ES2386272T3 (es) 2012-08-16
PL2179744T3 (pl) 2011-09-30
EP2236155A1 (en) 2010-10-06
EP2179744B1 (en) 2010-12-01
PT2578229E (pt) 2013-09-27
US8460914B2 (en) 2013-06-11
DE602005025170D1 (de) 2011-01-13
US9220768B2 (en) 2015-12-29
PL1789084T3 (pl) 2011-05-31
SI1789084T1 (sl) 2011-03-31
ES2357747T3 (es) 2011-04-29
JP2017057209A (ja) 2017-03-23
ES2432655T3 (es) 2013-12-04
DK2236155T3 (da) 2012-08-13
RS51665B (en) 2011-10-31
US20120034600A1 (en) 2012-02-09
HRP20100673T1 (hr) 2011-02-28
HRP20110007T1 (hr) 2011-04-30
RS52400B (en) 2013-02-28
US20190078060A1 (en) 2019-03-14
US20090081252A1 (en) 2009-03-26
JP2019210292A (ja) 2019-12-12
DK2578229T3 (da) 2013-10-07
JP2008512443A (ja) 2008-04-24
US20130122487A1 (en) 2013-05-16
CA2890962A1 (en) 2006-03-16
EP2471551A2 (en) 2012-07-04
RS51721B (en) 2011-10-31
CA2579859A1 (en) 2006-03-16
EP2179744A1 (en) 2010-04-28
HRP20120640T1 (hr) 2012-08-31
WO2006027698A1 (en) 2006-03-16
EP2578229B1 (en) 2013-07-10
JP2011207911A (ja) 2011-10-20
PL2236155T3 (pl) 2012-10-31
EP1789084B1 (en) 2010-11-17
JP2013100358A (ja) 2013-05-23
JP2015205929A (ja) 2015-11-19
HK1144374A1 (en) 2011-02-18
EP1789084A1 (en) 2007-05-30
US10155932B2 (en) 2018-12-18
SI2236155T1 (sl) 2012-09-28
SI2578229T1 (sl) 2013-10-30
PT2236155E (pt) 2012-07-19
PT2179744E (pt) 2011-03-09
CY1111208T1 (el) 2015-06-11
EP2578229A1 (en) 2013-04-10
DK2179744T3 (da) 2011-01-31
US20130129782A1 (en) 2013-05-23
EP2471551B1 (en) 2017-02-01
PL2578229T3 (pl) 2014-01-31
EP2471551A3 (en) 2012-11-14
CY1113225T1 (el) 2016-04-13
JP2012025784A (ja) 2012-02-09
US10954493B2 (en) 2021-03-23
CY1111180T1 (el) 2015-06-11
DE602005024827D1 (de) 2010-12-30
ATE488248T1 (de) 2010-12-15
ATE489965T1 (de) 2010-12-15
US9358280B2 (en) 2016-06-07
US20160251631A1 (en) 2016-09-01
DE12193096T1 (de) 2013-07-25

Similar Documents

Publication Publication Date Title
HRP20130962T1 (hr) Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva
JP2012025784A5 (hr)
Karakus et al. Propagation and titration of influenza viruses
Balish et al. Influenza: propagation, quantification, and storage
KR101316350B1 (ko) 인플루엔자 백신 조성물의 제조 방법
ES2653197T3 (es) Procedimiento para producir antígeno ortomixoviral y vacunas
KR20090088944A (ko) 배양물 속에서 인플루엔자 바이러스를 복제하는 방법
US20140315277A1 (en) Novel method
CN110305898A (zh) 哺乳动物细胞非易感h9n2亚型冷适应禽流感病毒的拯救
US10336988B2 (en) Methods for purification of a virus produced in vitro and clearance assay for the virus
Zhang et al. Isolation of swine influenza A virus in cell cultures and embryonated chicken eggs
US20180299444A1 (en) Sample quantification by disc centrifugation
CN110520525B (zh) 流感工作病毒种苗与制备、增加其感染力及制备疫苗方法
Afzal et al. Assessment of mumps virus growth on various continuous cell lines by virological, immunological, molecular and morphological investigations
Matsuda et al. Agroinfiltration of leaves for deconstructed viral vector-based transient gene expression: infiltrated leaf area affects recombinant hemagglutinin yield
Corredor et al. Fowl adenovirus-based vaccine platform
BRPI0914805B1 (pt) método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição
Kumar et al. Use of PCR-based assays for the detection of the adventitious agent porcine circovirus type 1 (PCV1) in vaccines, and for confirming the identity of cell substrates and viruses used in vaccine production
CN106520828A (zh) 一种玉米整株trv载体介导病毒诱导基因沉默方法
Huo et al. Artificial feeding Rice stripe virus enables efficient virus infection of Laodelphax striatellus
CN109294999B (zh) 适合犬瘟热病毒和禽流感病毒增殖的MDCK-KOmavs细胞系及应用
CN108795886B (zh) 一种病毒液的浓缩方法
CN104073472B (zh) 一种去除pcv2病毒中支原体污染的方法
Orbović et al. The use of Citrus tristeza virus (CTV) containing a green fluorescent protein gene as a tool to evaluate resistance/tolerance of transgenic citrus plants
Rao Preparation and inoculation of mesophyll protoplasts from monocotyledenous and dicotyledenous hosts